💊 TANDEM Triumph: Dual Power for LDL Cholesterol Reduction!
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
🚀 TANDEM Trial: Combining Obicetrapib & Ezetimibe for a powerful LDL reduction! 💊 ✅ -48.6% vs placebo, -27.9% vs Ezetimibe, -16.8% vs Obicetrapib 💪 Safe, effective, and oral! #Cardiology #LipidManagement #ASCVD
info_outline
Fungal Pharmacists, Fatty Liver, Future Frontiers 🧬🩸🍄
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
A gut fungus 🍄 (Fusarium foetens) secretes FF-C1 🧪, a metabolite that inhibits CerS6 and lowers ceramides 🩸—shielding mice from MASH 🛡️. Fungi aren’t just freeloaders—they may be our next therapeutic allies! 💊🧠 #Microbiome #LiverHealth #FungalTherapy #Science
info_outline
💪 Powerful Cholesterol Control: Obicetrapib in the Spotlight 🌟
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
🚀 Obicetrapib: A Breakthrough in LDL Lowering! 📉 Reduced LDL by 29.9% in high-risk patients (p<0.001) 💡 Promising adjunct to lipid-lowering therapy! #Cardiology #LipidManagement #HeartHealth 💓
info_outline
Fat Chance! 🔬🧬 Middle-Age Spread Starts at the Cellular Level
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
Here’s a tweet with emojis based on the article: 🧬 Middle-age spread decoded! 🕰️ Visceral fat grows in midlife not from bigger cells—but new ones! 🎯 CP-A cells fire up fat formation via LIFR–STAT3 🔥 💊 Targeting them may halt metabolic disease before it starts. #Aging #Obesity #CellBiology #Metabolism 🧫 Would you like a version with a more humorous tone or one tailored for clinicians?
info_outline
🔍📊🛡️ Detect, Decode, Defend: A New Era in Coronary Risk Prediction
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
🚨 New era in heart disease prediction! 🧬 + 🧪 + 🤖 = Meta-prediction model that beats PCE & QRISK3 📈 Detects hidden CAD risk in young, women & “low-risk” groups 🎯 Precision prevention just got personal. 🫀 Published in Nature Medicine #CardioTwitter #AI #Genomics #CAD
info_outline
Dr RR Baliga's Philosophical Discourses: Epicurus (Greece, 341–270 BCE) – Founder of Epicureanism
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
Epicurus (341–270 BC) was an ancient Greek philosopher who founded Epicureanism, emphasizing the pursuit of a tranquil, happy life through ataraxia (freedom from fear) and aponia (absence of pain). His teachings combined atomism, ethics, and naturalistic theology, advocating simple living, friendship, and the rejection of superstition.
info_outline
Calcium Wars: Orbital Atherectomy vs. Balloon Angioplasty — The ECLIPSE Verdict ⚔️🧠💔
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
🚨ECLIPSE Trial Results🚨 Orbital atherectomy 🌀 vs. balloon angioplasty 🎈 before stenting in severe coronary calcification 💔 🎯 No added benefit with atherectomy 🧠 Balloon-first + imaging = smart strategy 📊 Lancet 2025 | #CardioTwitter #InterventionalCardiology #ECLIPSETrial
info_outline
Genes 🧬, Journeys 🌍, and Hidden Hazards ⚡: Unlocking Health with Exposomics
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
“Your DNA 🧬 is just half the story — your exposome 🌍 writes the rest! From air 🌫️ to food 🍎 to stress 😰, exposomics unlocks the hidden drivers of health 🔍💥. Predict. Prevent. Prosper. 🚀 #Exposomics #PrecisionMedicine”
info_outline
. 🧩📉 “Unstiff the Heart: Cracking the Code of Cardiac Scars” 🫀🧬
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
🫀💊 Scientists found a way to trick heart cells into calming down! Blocking stiffness signals with a smart drug combo reduced scarring and helped hearts pump better in mice. A big step toward #mechanotherapy! 🧠🔬🐭 #CardioTwitter #Fibrosis #HeartHealth
info_outline
“Hope or Hype? Surveillance, Survival, and the Truth About Metastases 🔬⚖️🕯️”
Dr. Baliga's 'Got Knowledge Doc?' PODKASTS
🧪 Routine scans after cancer treatment: lifesaver or false security? 😰 Evidence shows no survival benefit, but lots of scanxiety, cost, and early toxicity. 💡 Sometimes, less is more. Ask why before you scan. #CancerSurveillance #Oncology 🩺📉
info_outline🔬 BEAM-302 is a liver-targeting gene therapy using base editing to correct the PiZ mutation in Alpha-1 Antitrypsin Deficiency (AATD). 🧬 I
t increases functional AAT 🫁 while reducing toxic Z-AAT, showing up to 78% reduction at the 60 mg dose. 📊
The Phase 1/2 trial demonstrated dose-dependent efficacy, a well-tolerated safety profile, and no serious adverse events (SAEs). 🛡️
With ongoing dose escalation and expansion to liver disease patients, BEAM-302 could be a one-time curative therapy 🚀, with further data expected in late 2025. 📅